Incyte

Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways

Retrieved on: 
Wednesday, January 24, 2024

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.
  • Synnovation was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics.
  • Proceeds will fund the advancement of the company’s clinical and preclinical pipeline, including SNV1521 and SNV4818, as well as additional programs.
  • The company’s lead program, SNV1521, is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, November 14, 2023

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.
  • In October 2023, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., effective December 1, 2023.
  • General and administrative expenses were $7.8 million for the third quarter of 2023, as compared to $8.1 million for the third quarter of 2022.
  • ET to discuss these third quarter 2023 financial results and provide a corporate update.

Immunome Appoints Jean-Jacques Bienaimé to Board of Directors

Retrieved on: 
Wednesday, November 8, 2023

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors.

Key Points: 
  • Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors.
  • Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals.
  • “Immunome is pleased to welcome JJ to the Board of Directors as we enter our next stage of growth,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
  • His guidance will be essential as we advance our pipeline of potential first-in-class and best-in-class targeted cancer therapies.”
    “I am excited to join the Immunome Board of Directors as they work to bring transformative oncology therapeutics to the patients most in need,” commented Mr. Bienaimé.

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter and provided a business update.

Key Points: 
  • In the planned trial, patients will be randomized to petosemtamab monotherapy or investigators’ choice of single agent chemotherapy or cetuximab.
  • Merus also continues to enroll patients with previously untreated advanced PD-L1+ HNSCC with petosemtamab 1500 mg in combination with Keytruda®.
  • Initial safety data from this single arm cohort may support the initiation of a first-line registration trial with this combination.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.

Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023

Retrieved on: 
Friday, October 27, 2023

Science magazine announced today that for the sixth consecutive year, Incyte has been named a top five employer based on its annual survey of approximately 6,800 individuals.

Key Points: 
  • Science magazine announced today that for the sixth consecutive year, Incyte has been named a top five employer based on its annual survey of approximately 6,800 individuals.
  • Incyte ranked second on this year’s list, two spots higher than its 2022 ranking, and was specifically recognized for its loyal employees, social responsibility and treating employees with respect.
  • Incyte is proud to be recognized as a top employer by Science and seeks to create an environment where innovation, collaboration and respect for each other are prioritized.
  • The complete Science magazine Top Employers survey feature, along with individual company rankings, is available in the October 27, 2023 print issue of Science and online: https://www.science.org/content/article/making-happy-workplace-employees .

Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023

WALTHAM, Mass., Nov. 2, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that results from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (cGVHD), will be featured during the Plenary Scientific Session at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023, in San Diego, California.

Key Points: 
  • "Inclusion of AGAVE-201 in this year's ASH plenary session further supports our belief that axatilimab has the potential to serve as a highly differentiated therapeutic option for patients with chronic GVHD," said Michael A. Metzger, Chief Executive Officer.
  • "We believe axatilimab's best-in-category profile and unique mechanism of action positions it as an important addition to the chronic GVHD treatment armamentarium, if approved.
  • Furthermore, axatilimab was generally well tolerated, and the most common adverse events were consistent with on-target effects and prior trials.
  • In addition, preclinical data detailing the anti-inflammatory and anti-fibrotic mechanism through which axatilimab is thought to impact the disease process in cGVHD will be featured during a poster session.

Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List

Retrieved on: 
Thursday, October 26, 2023

BRIDGEWATER, N.J., Oct. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has earned the highest ranking in Science's 2023 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics.

Key Points: 
  • The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics.
  • "At Insmed, we know that our people are our most valuable asset, and it is because of them that we have received this honor once again.
  • The 2023 survey results were based on more than 6,800 responses from individuals across North America (59%), Europe (18%), Asia/Pacific Rim (16%), and other locations (7%).
  • Following Insmed, the top five companies in 2023 included Incyte, Alnylam, Regeneron, and Syngenta Group.

EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies

Retrieved on: 
Thursday, October 26, 2023

BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies

Key Points: 
  • BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
    The issuer is solely responsible for the content of this announcement.
  • The rise in bond yields weighed heavily on biotech stocks as well as the stock market in general.
  • BB Biotech benefited from the dollar's appreciation, but it was also exposed to the sustained selling pressure on equity markets.
  • BB Biotech traded within a narrow range during the third quarter, closing slightly higher at CHF 41.35 per share.

Elevar Therapeutics Names Brian Cunningham Vice President of Sales and Kenneth Rankin Vice President of Market Access, Strengthening Commercial Leadership in Buildup to Launch

Retrieved on: 
Monday, October 23, 2023

"The additions of Brian Cunningham and Kenneth Rankin come at an important and exciting time for Elevar, as we position the company for a potential commercial launch in the coming year,” said Elevar Chief Commercial Officer Paul Friel.

Key Points: 
  • "The additions of Brian Cunningham and Kenneth Rankin come at an important and exciting time for Elevar, as we position the company for a potential commercial launch in the coming year,” said Elevar Chief Commercial Officer Paul Friel.
  • “Both possess a wealth of sales and management acumen, and a great understanding of the road ahead for our company.
  • Cunningham joins Elevar from global oncology company Novocure, where he served as the national sales and operations lead for its Central Nervous System Cancers Franchise.
  • He was previously vice president of sales for rare commercial services at Dohmen Life Science Services, and director of Eisai Inc.’s government payer team.

1859 Strengthens Leadership with Appointment of Consulting CSO and Strategic Pharma Advisors, Bringing Deep Oncology and Immunology Expertise

Retrieved on: 
Monday, October 23, 2023

"We are proud to welcome Jeff, Venkat and Michael to 1859 during this pivotal time for the company," said 1859 CEO, Sanket Agrawal.

Key Points: 
  • "We are proud to welcome Jeff, Venkat and Michael to 1859 during this pivotal time for the company," said 1859 CEO, Sanket Agrawal.
  • "With their therapeutic expertise in oncology and immunology, and track record in creating and leading biotech companies to clinical assets, we are poised to continue pushing our strategic vision forward."
  • Continuing into 2024, 1859 will amplify and diversify its internal pipeline into high-value oncology, and immunology and inflammation therapeutic areas.
  • Venkat Reddy, Ph.D., Chief Scientific Officer at General Inception, brings deep expertise and a wealth of experience in oncology and autoimmune therapeutic areas.